These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues. Chiti A; van Graafeiland BJ; Savelli G; Ferrari L; Seregni E; Castellani MR; Bombardieri E Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S190-4. PubMed ID: 10604128 [TBL] [Abstract][Full Text] [Related]
3. [Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system]. Faiss S; Scherübl H; Bäder M; Fett U; Koppenhagen K; Wiedenmann B; Riecken EO Z Gastroenterol; 1994 May; 32(5):243-6. PubMed ID: 7915450 [TBL] [Abstract][Full Text] [Related]
4. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114 [TBL] [Abstract][Full Text] [Related]
5. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127 [TBL] [Abstract][Full Text] [Related]
6. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors. Bal CS; Gupta SK; Zaknun JJ Trop Gastroenterol; 2010; 31(2):87-95. PubMed ID: 20862981 [TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. Jamar F; Fiasse R; Leners N; Pauwels S J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439 [TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Kwekkeboom DJ; de Herder WW; Krenning EP Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418 [TBL] [Abstract][Full Text] [Related]
14. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas]. Banzo J; Abós MD; Prats E; García F; Razola P Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088 [No Abstract] [Full Text] [Related]
15. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues]. Rubello D; Rufini V; De Carlo E; Martini C; Calcagni ML; Sicolo N; Troncone L; Casara D Minerva Endocrinol; 2003 Dec; 28(4):259-96. PubMed ID: 14752399 [TBL] [Abstract][Full Text] [Related]
16. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. John M; Meyerhof W; Richter D; Waser B; Schaer JC; Scherübl H; Boese-Landgraf J; Neuhaus P; Ziske C; Mölling K; Riecken EO; Reubi JC; Wiedenmann B Gut; 1996 Jan; 38(1):33-9. PubMed ID: 8566856 [TBL] [Abstract][Full Text] [Related]
17. Localisation of neuroendocrine tumours of the upper gastrointestinal tract. Zimmer T; Ziegler K; Bäder M; Fett U; Hamm B; Riecken EO; Wiedenmann B Gut; 1994 Apr; 35(4):471-5. PubMed ID: 8174983 [TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor scintigraphy: a first-line imaging modality for gastroenteropancreatic neuroendocrine tumors. Lebtahi R; Cadiot G; Mignon M; Le Guludec D Gastroenterology; 1998 Oct; 115(4):1025-7. PubMed ID: 9786730 [No Abstract] [Full Text] [Related]